Warnings In 2019, AERs In 2009: Touchstones Toward Homeopathic Guidance
Executive Summary
Priority enforcement areas listed in draft guidance note delivery formats other than oral and topical, such as nasal gel product that was early alarm in FDA's evaluation of safety and efficacy across homeopathic market. Recent warnings also noted in revised draft.
You may also be interested in...
US Health Market In 2019: Unfinished Business Leaves Lasting Impression
Examples of unfinished business from 2019 include no legislation passed to reform OTC monograph program; FDA putting off until May the planned publication of an NPRM to allow firms to submit OTC NDAs with extra-label information to help guide consumers' self-selection; and no OTC naloxone for opioid overdose approved even after FDA's unprecedented step of developing model DFLs sponsors could use for their own label comprehension studies.
Homeopathic Firm's Teething Remedy Touches FDA Enforcement Nerve
FDA warns OHM Pharma for promoting topical formula containing homeopathic ingredients as teething product for infants. The firm also warned about drug and supplements GMP violations and was an easy target for FDA following release of draft guidance outlining its enforcement priorities.
Latest Steps In FDA Homeopathy Policy Overhaul Prompt Trade Group Questions
A revised draft introduces list of risk-based enforcement priorities but doesn't necessarily tighten FDA oversight of homeopathics manufacturing and marketing, say CHPA and AIH.